FORM 8-K |
Zoetis Inc. |
(Exact name of registrant as specified in its charter) |
Delaware | 001-35797 | 46-0696167 | ||
(State or other jurisdiction | (Commission File | (I.R.S. Employer | ||
of incorporation) | Number) | Identification No.) |
10 Sylvan Way, Parsippany, New Jersey | 07054 | |
(Address of principal executive offices) | (Zip Code) |
(973) 822-7000 |
(Registrant's telephone number, including area code) |
Not Applicable |
(Former Name or Former Address, if changed since last report) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.01 per share | ZTS | New York Stock Exchange |
(d) | Exhibits |
Exhibit No. | Description |
Press Release of Zoetis Inc. dated May 2, 2019, reporting Zoetis' financial results for the | |
first quarter of 2019 and updating its guidance for full year 2019. | |
Zoetis Inc. | ||
May 2, 2019 | By: | /S/ GLENN DAVID |
Glenn David | ||
Executive Vice President and | ||
Chief Financial Officer |
• | Reports Revenue of $1.5 Billion, Growing 7%, and Net Income of $312 Million, or $0.65 per Diluted Share, Decreasing 11% and 10%, respectively, on a Reported Basis for First Quarter 2019 |
• | Reports Adjusted Net Income of $424 Million, or Adjusted Diluted EPS of $0.88, for First Quarter 2019 |
• | Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for First Quarter 2019 |
• | Updates Full Year 2019 Revenue Guidance to $6.100 - $6.225 Billion and Diluted EPS of $2.79 - $2.93 on a Reported Basis, or $3.42 - $3.52 on an Adjusted Basis |
• | Revenue in the U.S. segment was $718 million, an increase of 13% compared with the first quarter of 2018. Sales of companion animal products grew 30% driven primarily by the acquisition of Abaxis, parasiticides (mainly Revolution® Plus for cats and Simparica® for dogs), and key dermatology products. Sales of livestock products declined 7% in the quarter, with declines in cattle and swine more than offsetting growth in poultry. Our cattle and swine product sales were impacted by the timing of distributor purchasing patterns for medicated feed additive products. Poultry growth was largely due to increased sales of our portfolio of alternatives to antibiotics in medicated feed additives. |
• | Revenue in the International segment was $718 million, a decrease of 1% on a reported basis and an increase of 7% operationally compared with the first quarter of 2018. Sales of companion animal products grew 15% on a reported basis and 23% on an operational basis. Growth resulted primarily from increased sales across our key dermatology portfolio, the acquisition of Abaxis, and Simparica. Sales of livestock products declined 9% on a reported basis and 1% operationally, due to the negative impact of African Swine Fever in China, as well as the divestiture of certain agribusiness products in Japan; this decline was partially offset by growth across poultry, fish and sheep. |
• | Revenue between $6.100 billion and $6.225 billion |
• | Reported diluted EPS between $2.79 and $2.93 |
• | Adjusted diluted EPS between $3.42 and $3.52 |
Media Contacts: | Investor Contacts: | |
Kristen Seely | Steve Frank | |
1-973-443-2777 (o) | 1-973-822-7141 (o) | |
kristen.seely@zoetis.com | steve.frank@zoetis.com | |
Elinore White | Marissa Patel | |
1-973-443-2835 (o) | 1-973-443-2996 (o) | |
elinore.y.white@zoetis.com | marissa.patel@zoetis.com |
First Quarter | |||||||||
2019 | 2018 | % Change | |||||||
Revenue | $ | 1,455 | $ | 1,366 | 7 | ||||
Costs and expenses: | |||||||||
Cost of sales | 518 | 447 | 16 | ||||||
Selling, general and administrative expenses | 369 | 338 | 9 | ||||||
Research and development expenses | 102 | 97 | 5 | ||||||
Amortization of intangible assets | 38 | 23 | 65 | ||||||
Restructuring charges and certain acquisition-related costs | 5 | 2 | * | ||||||
Interest expense | 56 | 47 | 19 | ||||||
Other (income)/deductions–net | (14 | ) | (5 | ) | * | ||||
Income before provision for taxes on income | 381 | 417 | (9) | ||||||
Provision for taxes on income | 69 | 67 | 3 | ||||||
Net income before allocation to noncontrolling interests | 312 | 350 | (11) | ||||||
Less: Net income/(loss) attributable to noncontrolling interests | — | (2 | ) | (100) | |||||
Net income attributable to Zoetis | $ | 312 | $ | 352 | (11) | ||||
Earnings per share—basic | $ | 0.65 | $ | 0.72 | (10) | ||||
Earnings per share—diluted | $ | 0.65 | $ | 0.72 | (10) | ||||
Weighted-average shares used to calculate earnings per share | |||||||||
Basic | 479.6 | 485.9 | |||||||
Diluted | 483.1 | 489.8 | |||||||
(a) | The condensed consolidated statements of income present the first quarter ended March 31, 2019 and March 31, 2018. Subsidiaries operating outside the United States are included for the first quarter ended February 28, 2019 and February 28, 2018. |
Quarter ended March 31, 2019 | |||||||||||||||||||
GAAP Reported(a) | Purchase Accounting Adjustments | Acquisition- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(b) | |||||||||||||||
Cost of sales(c) | $ | 518 | $ | (14 | ) | $ | — | $ | (70 | ) | $ | 434 | |||||||
Gross profit | 937 | 14 | — | 70 | 1,021 | ||||||||||||||
Selling, general and administrative expenses(c) | 369 | (18 | ) | — | — | 351 | |||||||||||||
Amortization of intangible assets(d) | 38 | (34 | ) | — | — | 4 | |||||||||||||
Restructuring charges and certain acquisition-related costs | 5 | — | (5 | ) | — | — | |||||||||||||
Income before provision for taxes on income | 381 | 66 | 5 | 70 | 522 | ||||||||||||||
Provision for taxes on income | 69 | 20 | 1 | 8 | 98 | ||||||||||||||
Net income attributable to Zoetis | 312 | 46 | 4 | 62 | 424 | ||||||||||||||
Earnings per common share attributable to Zoetis–diluted | 0.65 | 0.09 | 0.01 | 0.13 | 0.88 | ||||||||||||||
Quarter ended March 31, 2018 | |||||||||||||||||||
GAAP Reported(a) | Purchase Accounting Adjustments | Acquisition- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(b) | |||||||||||||||
Cost of sales(c) | $ | 447 | $ | (2 | ) | $ | — | $ | (1 | ) | $ | 444 | |||||||
Gross profit | 919 | 2 | — | 1 | 922 | ||||||||||||||
Selling, general and administrative expenses(c) | 338 | (1 | ) | — | (1 | ) | 336 | ||||||||||||
Research and development expenses(c) | 97 | (1 | ) | — | — | 96 | |||||||||||||
Amortization of intangible assets(d) | 23 | (19 | ) | — | — | 4 | |||||||||||||
Restructuring charges and certain acquisition-related costs | 2 | — | (1 | ) | (1 | ) | — | ||||||||||||
Income before provision for taxes on income | 417 | 23 | 1 | 3 | 444 | ||||||||||||||
Provision for taxes on income | 67 | 11 | — | 3 | 81 | ||||||||||||||
Net income attributable to Zoetis | 352 | 12 | 1 | — | 365 | ||||||||||||||
Earnings per common share attributable to Zoetis–diluted | 0.72 | 0.03 | — | — | 0.75 |
(a) | The condensed consolidated statements of income present the first quarter ended March 31, 2019 and March 31, 2018. Subsidiaries operating outside the United States are included for the first quarter ended February 28, 2019 and February 28, 2018. |
(b) | Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. |
(c) | Exclusive of amortization of intangible assets, except as discussed in footnote (d) below. |
(d) | Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. |
(1) | Acquisition-related costs include the following: |
First Quarter | |||||||
2019 | 2018 | ||||||
Integration costs(a) | $ | 1 | $ | 1 | |||
Restructuring charges(b) | 4 | — | |||||
Total acquisition-related costs—pre-tax | 5 | 1 | |||||
Income taxes(c) | 1 | — | |||||
Total acquisition-related costs—net of tax | $ | 4 | $ | 1 |
(a) | Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs. |
(b) | Represents employee termination costs, included in Restructuring charges and certain acquisition-related costs. |
(c) | Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. |
(2) | Certain significant items include the following: |
First Quarter | |||||||
2019 | 2018 | ||||||
Supply network strategy(a) | $ | 2 | $ | 2 | |||
Other(b) | 68 | 1 | |||||
Total certain significant items—pre-tax | 70 | 3 | |||||
Income taxes(c) | 8 | 3 | |||||
Total certain significant items—net of tax | $ | 62 | $ | — |
(a) | Represents consulting fees, included in Cost of sales, related to cost-reduction and productivity initiatives. |
(b) | For the three months ended March 31, 2019, represents a change in estimate related to inventory costing, included in Cost of sales. |
(c) | Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. For the first quarter ended March 31, 2018, also includes a net tax benefit related to a measurement-period adjustment to the provisional one-time mandatory deemed repatriation tax on the company's undistributed non-U.S. earnings pursuant to the Tax Cuts and Jobs Act. |
First Quarter | % Change | |||||||||||||||||
2019 | 2018 | Total | Foreign Exchange | Operational(b) | ||||||||||||||
Adjusted cost of sales | $ | 434 | $ | 444 | (2 | )% | (6 | )% | 4 | % | ||||||||
as a percent of revenue | 29.8 | % | 32.5 | % | NA | NA | NA | |||||||||||
Adjusted SG&A expenses | 351 | 336 | 4 | % | (4 | )% | 8 | % | ||||||||||
Adjusted R&D expenses | 102 | 96 | 6 | % | (2 | )% | 8 | % | ||||||||||
Adjusted net income attributable to Zoetis | 424 | 365 | 16 | % | (2 | )% | 18 | % | ||||||||||
(a) | Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income attributable to Zoetis (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Operations and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. |
(b) | Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
Selected Line Items (millions of dollars, except per share amounts) | Full Year 2019 |
Revenue | $6,100 to $6,225 |
Operational growth(a) | 7.5% to 9.5% |
Organic operational growth(b) | 4.5% to 6.5% |
Adjusted cost of sales as a percentage of revenue(c) | 31% to 32% |
Adjusted SG&A expenses(c) | $1,450 to $1,500 |
Adjusted R&D expenses(c) | $445 to $465 |
Adjusted interest expense and other (income)/deductions(c) | Approximately $200 |
Effective tax rate on adjusted income(c) | 20% to 21% |
Adjusted diluted EPS(c) | $3.42 to $3.52 |
Adjusted net income(c) | $1,650 to $1,700 |
Operational growth(a)(d) | 8% to 11% |
Certain significant items and acquisition-related costs(e) | $130 to $150 |
(millions of dollars, except per share amounts) | Reported | Certain significant items and acquisition-related costs(e) | Purchase accounting | Adjusted(c) | |
Cost of sales as a percentage of revenue | 32.8% - 33.8% | ~ (1.3%) | ~ (0.5%) | 31% - 32% | |
SG&A expenses | $1,525 to $1,575 | ($75) | $1,450 to $1,500 | ||
R&D expenses | $447 to $467 | ($2) | $445 to $465 | ||
Interest expense and other (income)/deductions | ~ $200 | ~ $200 | |||
Effective tax rate | 20% to 21% | 20% to 21% | |||
Diluted EPS | $2.79 to $2.93 | $0.22 to $0.26 | $0.37 | $3.42 to $3.52 | |
Net income attributable to Zoetis | $1,345 to $1,415 | $105 to $125 | ~ $180 | $1,650 to $1,700 |
(a) | Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange. |
(b) | Organic operational growth (a non-GAAP financial measure) excludes the impact of the acquisition of Abaxis as well as foreign exchange. |
(c) | Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted interest expense and other (income)/deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. |
(d) | We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. |
(e) | Primarily includes certain nonrecurring costs related to the acquisition of Abaxis and other charges. |
First Quarter | % Change | |||||||||||||||||
2019 | 2018 | Total | Foreign Exchange | Operational(b) | ||||||||||||||
Revenue: | ||||||||||||||||||
Livestock | $ | 707 | $ | 770 | (8 | )% | (5 | )% | (3 | )% | ||||||||
Companion Animal | 729 | 590 | 24 | % | (3 | )% | 27 | % | ||||||||||
Contract Manufacturing & Human Health Diagnostics | 19 | 6 | * | * | * | |||||||||||||
Total Revenue | $ | 1,455 | $ | 1,366 | 7 | % | (4 | )% | 11 | % | ||||||||
U.S. | ||||||||||||||||||
Livestock | $ | 273 | $ | 292 | (7 | )% | — | % | (7 | )% | ||||||||
Companion Animal | 445 | 342 | 30 | % | — | % | 30 | % | ||||||||||
Total U.S. Revenue | $ | 718 | $ | 634 | 13 | % | — | % | 13 | % | ||||||||
International | ||||||||||||||||||
Livestock | $ | 434 | $ | 478 | (9 | )% | (8 | )% | (1 | )% | ||||||||
Companion Animal | 284 | 248 | 15 | % | (8 | )% | 23 | % | ||||||||||
Total International Revenue | $ | 718 | $ | 726 | (1 | )% | (8 | )% | 7 | % | ||||||||
Livestock: | ||||||||||||||||||
Cattle | $ | 380 | $ | 416 | (9 | )% | (6 | )% | (3 | )% | ||||||||
Swine | 149 | 175 | (15 | )% | (5 | )% | (10 | )% | ||||||||||
Poultry | 139 | 136 | 2 | % | (5 | )% | 7 | % | ||||||||||
Fish | 23 | 22 | 5 | % | (4 | )% | 9 | % | ||||||||||
Other | 16 | 21 | (24 | )% | (6 | )% | (18 | )% | ||||||||||
Total Livestock Revenue | $ | 707 | $ | 770 | (8 | )% | (5 | )% | (3 | )% | ||||||||
Companion Animal: | ||||||||||||||||||
Dogs and Cats | $ | 688 | $ | 549 | 25 | % | (4 | )% | 29 | % | ||||||||
Horses | 41 | 41 | — | % | (6 | )% | 6 | % | ||||||||||
Total Companion Animal Revenue | $ | 729 | $ | 590 | 24 | % | (3 | )% | 27 | % | ||||||||
(a) | For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. |
(b) | Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. |
First Quarter | % Change | |||||||||||||||||
2019 | 2018 | Total | Foreign Exchange | Operational(a) | ||||||||||||||
Total International | $ | 718.0 | $ | 725.9 | (1 | )% | (8 | )% | 7 | % | ||||||||
Australia | 48.0 | 47.6 | 1 | % | (9 | )% | 10 | % | ||||||||||
Brazil | 60.1 | 69.6 | (14 | )% | (15 | )% | 1 | % | ||||||||||
Canada | 41.1 | 40.2 | 2 | % | (6 | )% | 8 | % | ||||||||||
China | 59.5 | 63.9 | (7 | )% | (5 | )% | (2 | )% | ||||||||||
France | 32.3 | 33.2 | (3 | )% | (7 | )% | 4 | % | ||||||||||
Germany | 36.5 | 37.5 | (3 | )% | (6 | )% | 3 | % | ||||||||||
Italy | 28.1 | 27.1 | 4 | % | (6 | )% | 10 | % | ||||||||||
Japan | 37.3 | 40.9 | (9 | )% | — | % | (9 | )% | ||||||||||
Mexico | 28.1 | 24.4 | 15 | % | (3 | )% | 18 | % | ||||||||||
Spain | 27.1 | 25.3 | 7 | % | (6 | )% | 13 | % | ||||||||||
United Kingdom | 56.7 | 52.1 | 9 | % | (7 | )% | 16 | % | ||||||||||
Other developed markets | 83.8 | 79.3 | 6 | % | (6 | )% | 12 | % | ||||||||||
Other emerging markets | 179.4 | 184.8 | (3 | )% | (11 | )% | 8 | % |
(a) | Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. |
First Quarter | % Change | |||||||||||||||||
2019 | 2018 | Total | Foreign Exchange | Operational(b) | ||||||||||||||
U.S.: | ||||||||||||||||||
Revenue | $ | 718 | $ | 634 | 13 | % | — | % | 13 | % | ||||||||
Cost of Sales | 147 | 140 | 5 | % | — | % | 5 | % | ||||||||||
Gross Profit | 571 | 494 | 16 | % | — | % | 16 | % | ||||||||||
Gross Margin | 79.5 | % | 77.9 | % | ||||||||||||||
Operating Expenses | 110 | 96 | 15 | % | — | % | 15 | % | ||||||||||
Other (income)/deductions | — | — | — | % | — | % | — | % | ||||||||||
U.S. Earnings | $ | 461 | $ | 398 | 16 | % | — | % | 16 | % | ||||||||
International: | ||||||||||||||||||
Revenue | $ | 718 | $ | 726 | (1 | )% | (8 | )% | 7 | % | ||||||||
Cost of Sales | 210 | 234 | (10 | )% | (10 | )% | — | % | ||||||||||
Gross Profit | 508 | 492 | 3 | % | (7 | )% | 10 | % | ||||||||||
Gross Margin | 70.8 | % | 67.8 | % | ||||||||||||||
Operating Expenses | 132 | 133 | (1 | )% | (11 | )% | 10 | % | ||||||||||
Other (income)/deductions | — | 1 | * | * | * | |||||||||||||
International Earnings | $ | 376 | $ | 358 | 5 | % | (5 | )% | 10 | % | ||||||||
Total Reportable Segments | $ | 837 | $ | 756 | 11 | % | (2 | )% | 13 | % | ||||||||
Other business activities(c) | (80 | ) | (81 | ) | (1 | )% | ||||||||||||
Reconciling Items: | ||||||||||||||||||
Corporate(d) | (162 | ) | (153 | ) | 6 | % | ||||||||||||
Purchase accounting adjustments(e) | (66 | ) | (23 | ) | * | |||||||||||||
Acquisition-related costs(f) | (5 | ) | (1 | ) | * | |||||||||||||
Certain significant items(g) | (70 | ) | (3 | ) | * | |||||||||||||
Other unallocated(h) | (73 | ) | (78 | ) | (6 | )% | ||||||||||||
Total Earnings(i) | $ | 381 | $ | 417 | (9 | )% |
(a) | For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. |
(b) | Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
(c) | Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health diagnostic business. |
(d) | Corporate includes, among other things, administration expenses, interest expense, certain compensation costs, certain procurement costs, and other costs not charged to our operating segments. |
(e) | Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. |
(f) | Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. |
(g) | Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative and supply network strategy, and the impact of divestiture-related gains and losses. |
(h) | Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. |
(i) | Defined as income before provision for taxes on income. |
D!\@'Z @,"# (4 AT")@(O C@"00)+
M E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0, PL#%@,A RT#
M. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(
M!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'
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M&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=
M:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^
M8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z& '!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"
M70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0, PL#%@,A RT#. -#
M T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$
M8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'
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M%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=:AZ4
M'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["
M?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z& 1I&_FQZ4OLSZ)^O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z8,]M;;.Z:846Y]NX+ +H( 0IEJJVLEAIX5+$ :F%V( N2![0;EN>V[/8W.Y;K?0VNW
MPKJ>65U1$'JS,0!^9R<<>C/9]EW?F' _=>Z][]U[KWOW7NE1LG>.?Z]W?MK?&UJU\=N+:F:Q^=P]6ER(JW
M'5"5$2S("!-2S:-$T9],L3,C75B/9UL.];CRYO.U[]M,YBW*SG26-O1D8$5'
MFII1EX,I*G!/1!S/RYM/.'+V]\K[[;";9[^VD@F0^:2*5-#^%A74C#*L PR!
MUN0=-=GX7N;J[8_:& ]&-WE@*/*?:^02OCLAZZ;,8B:10 ]3A\M3STLA'!>$
MD<>^UO)/-5ASORGL/->W8MKVW6336I1_ADC)\S'(&C/S4]?.'[D%I\ENBIEM?U1P
MY+#48(_U4BGWBI][_?/W=[5P;6C?J[AN4,9'JD0>=C]@>./\R.LXON
M_=>Z(S\QOFULKXN8)L11+2;J[
M./\ 3SM#&?\ ;001$?(CH@OO';K+3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMFW^51LO^[/Q5HL_)
M%HG["WQNO]^Z]U[W[KW7O?NO=>]^Z]TZX' YO=.9QNW=MXG(Y[/9FKBH<7A\31SY#)9&
MLG-HJ:CHJ9'GGF<_A5/'/T'LPV_;[[=[ZUVW;+.6XW&9PD<<:EW=CP554$DG
MT Z+=UW;;-AVV]WG>MPAM-IMHR\LTKK''&B\6=V(50/4GJZWXU_RF354^/W7
M\E,O44IE6*IBZOVM7(E1$I(80;JW53&41R%;B2FQAU+<$5@-T&3J&<-Y^ AJL"@UIHK(1AY'ZXC>]7WH_MPN%BB7R!.6=R =,<:!I)'I1(U9C@=:@W?\ W?NOY"]I;D[-
MW7*R3Y:H^VPN)69I:3;>VZ221@*"X5?%0P.3(X5?/4R2S,-
YW)DWWER5;4DFK-:.I:S8_P"E59+=
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M==XM_;;:+C_=?8,);LJ
A<357Q^U:5-\[OCC>Z2;B
MS,$U)MRBJ%O=)<5@'FJ +69,HA^J\<[_ +Y?/1O=XV/V_LYO\7LT%U< '!FE
M!6%3\XX2S_,3CTZZS_W>7MDNW\O\S^Z^X0?XW?R&RM"1D6\+*]PZGS$LX2/U
M!MF' ]4Q>\'NNE/7O?NO=>]^Z]U[W[KW66GIZBJGAI::*6HJ:F6.GIZ>%&EE
MGGF=8XH8HT'DDEED(55 ))-A[?CCDFD2**,M*Q J22: >9)P!TS-+%!#+
M//*J0HI9F)H%4"I))P !DD\!UN%?%CI>EZ#Z)V#UPD$468H<1%E-W3QZ&-9O
M#,JM?N&9YEO]Q'35LII8'//VM/$OT4#WVB]I>1XO;WD'E[ED1J+V.$27!'XK
MF7OF-?,*QT*?X$0C$>Y(ZB+KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZAU=724%+45U?5
M4]%14<4M35UE7-%34M+3PH9)IZFHF=(H(8D4LS,P50+D^V)IH;:.2XN)5C@1
M2S,Q"JH&26)H ,DDT'3UO;SW<\-K:0/+
]^Z]U[W[KW7O?NO=>
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MWW9]G>=_9GF.7E[G#;2B,6-O!ZPV[53C96S#*+C]<)W%N$0NT%9N2O@N."\5%$QAA
M)O++-R:]Z?>C>?=O>Z]]ORK;.?I;:OY>--0T:9Q]JQ*="$][OW;^[G]W;E[V
M'Y;T_IW?/-Y&OUMY3[#]/;U 9+=&^0:9QXD@%(XXR;>X.ZR2Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NK9_Y?WP'F[:J<5W/W'BIJ?JZCG6JVKM:L1XINPZNGDN
ME=71, Z;,IYDY^AR#KH'[